Azacitidine for blood chimerism changes after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an allogeneic stem cell transplant and are now 30–180 days past it
- You have a drop in donor chimerism after day 30 OR your day 30/day 100 myeloid chimerism is under 98%
- Your bone marrow looks like it is NOT actively relapsing at those time points (less than 5% blasts)
- Your blood counts are adequate: ANC over 1000 and platelets over 50,000
- Your organs can handle treatment: kidney function (creatinine clearance over 60) and liver tests (bilirubin under 1.5; liver enzymes under 2.5× normal)
- You cannot have certain infections or illnesses: no uncontrolled infection, no hepatitis B/C or HIV, and no cirrhosis
- You need to be able to do treatment basics: age 18–75, enough strength to function (Karnofsky at least 70%), and sign consent
- You must be off chemo, radiation, or other study drugs for at least 2 weeks before starting
- If you’re a woman who could become pregnant, you must have a negative pregnancy test and use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This study tests whether giving a drug called azacitidine along with donor lymphocyte infusions (white blood cells from your original donor) can help prevent leukemia from coming back after a stem cell transplant. If you are at high risk for relapse, this combination might lower that risk.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.